Latanoprost/Timolol Elvim (Timolol Maleate, Latanoprost)

The drug combines two mechanisms: latanoprost, a prostaglandin analog, enhances uveoscleral outflow of aqueous humor, while timolol, a non‑selective beta‑blocker, reduces aqueous humor production by blocking beta‑adrenergic receptors in the ciliary body. Together they provide a greater overall reduction in intra‑ocular pressure than either agent alone.

The prescribed dosing regimen is determined by the treating ophthalmologist based on the individual patient's condition, response, and tolerance. Typically, one drop is instilled into the affected eye(s) once daily, but the exact dose and timing should follow the prescriber’s instructions.

Safety data for use in pregnancy and lactation are limited. The product should be used only if the potential therapeutic benefit justifies any potential risk to the fetus or infant. Physicians should discuss the risk‑benefit profile with the patient before initiating therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with monotherapy agents, the fixed‑dose combination offers the convenience of a single drop and synergistic pressure‑lowering effects. It often achieves greater IOP reduction than either latanoprost or timolol alone and may reduce the need for additional medications, improving adherence.

The ophthalmic solution should be stored at room temperature, below 25 °C, in its original container. Protect the bottle from light and moisture, and keep the cap tightly closed when not in use. Do not freeze the product.

The medication is applied as an eye drop. The patient should wash hands, tilt the head back, pull down the lower eyelid to create a small pocket, and place one drop into the conjunctival sac. Close the eye gently for a few seconds and avoid blinking excessively.

Serious risks include severe ocular pain, sudden vision loss, corneal ulceration, systemic bradycardia or hypotension, and exacerbation of asthma or chronic obstructive pulmonary disease. Any of these symptoms require immediate medical attention.

Patients with known hypersensitivity to timolol, latanoprost, or any excipients in the formulation should avoid the product. It is also contraindicated in individuals with severe bronchial asthma, chronic obstructive pulmonary disease, sinus bradycardia, or second‑ or third‑degree atrioventricular block unless specifically advised by a physician.